Canada
Related tags
Connection Vol. 15: HER2 in Gastric Cancer
Gastric cancer is the fourth most commonly diagnosed cancer. Recently, Trastuzumab® has been shown to improve the survival of patients with advanced gastric cancer. Dako also received approval from the U.S. FDA to expand the intended use for HercepTest™ and HER2 FISH pharmDx™ Kit to include patients with metastatic gastric or gastroesophageal junction adenocarcinoma. This issue of Connection is especially dedicated to inform and update both the practitioners and observers about the the emerging use of Trastuzumab® in gastric cancer, pharmacodiagnostics, and the salient differences between breast and gastric cancer HER2 testing.
Download the full Connection Vol. 15
Literature Order No. 28830
All articles that have been brought in Connection Vol. 15 are available below:
Connection 15 Articles
Editorial - HER2 in Gastric Cancer
Dec 14, 2010
Featured Laboratory - Queen Elizabeth Hospital
Dec 14, 2010
Breast vs. Gastric Cancer
Dec 14, 2010
Gastric Carcinoma
Dec 14, 2010
Overview of Trastuzumab's Utility for Gastric Cancer
Dec 14, 2010
HER2 Diagnostics in Gastric Cancer
Dec 14, 2010
Developing Pharmacodiagnostics for HER2 Postive Gastric Cancer
Dec 14, 2010
HER2 Testing in Gastric Cancer and Esophageal Adenocarcinoma: Emerging Therapeutic Options and Diagnostic Challenges
Dec 14, 2010
The ToGA (Trastuzumab for GAstric Cancer) Trial: Importance from a Biomarker Perspective
Dec 14, 2010
Gastric Cancer Treatment in Japan
Dec 14, 2010
HER2 Status: What is the Difference Between Breast and Gastric Cancer
Dec 14, 2010
HER2 Testing in Gastric / Gastro-Esophageal Junction Adenocarcinomas and Breast Cancer: Similiarities
Dec 14, 2010
